390 related articles for article (PubMed ID: 15383144)
1. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
3. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
Kremer M; Schnierle BS
Curr HIV Res; 2005 Oct; 3(4):339-44. PubMed ID: 16250885
[TBL] [Abstract][Full Text] [Related]
5. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
6. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
Kao S; Miyagi E; Khan MA; Takeuchi H; Opi S; Goila-Gaur R; Strebel K
Retrovirology; 2004 Sep; 1():27. PubMed ID: 15373943
[TBL] [Abstract][Full Text] [Related]
7. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
[TBL] [Abstract][Full Text] [Related]
8. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
9. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
[TBL] [Abstract][Full Text] [Related]
10. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A; Strack B; Ancuta P; Zhang C; McPike M; Gabuzda D
J Biol Chem; 2004 Feb; 279(9):7792-8. PubMed ID: 14672928
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
12. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W
Med Hypotheses; 2005; 64(2):261-3. PubMed ID: 15607551
[TBL] [Abstract][Full Text] [Related]
13. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
Ribeiro AC; Maia e Silva A; Santa-Marta M; Pombo A; Moniz-Pereira J; Goncalves J; Barahona I
J Virol; 2005 Jan; 79(2):823-33. PubMed ID: 15613310
[TBL] [Abstract][Full Text] [Related]
16. Complementary function of the two catalytic domains of APOBEC3G.
Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
[TBL] [Abstract][Full Text] [Related]
17. The viral infectivity factor (Vif) of HIV-1 unveiled.
Rose KM; Marin M; Kozak SL; Kabat D
Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
[TBL] [Abstract][Full Text] [Related]
18. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
Sawyer SL; Emerman M; Malik HS
PLoS Biol; 2004 Sep; 2(9):E275. PubMed ID: 15269786
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
Marin M; Rose KM; Kozak SL; Kabat D
Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
